Vaxfectin (TM)-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge

Next generation influenza vaccines containing conserved antigens may enhance immunity against seasonal or pandemic influenza virus strains. Using a plasmid DNA (pDNA)-based vaccine approach, we systematically tested combinations of NP, M1 and M2 antigens derived from consensus sequences for protection against lethal influenza challenge and compared formulations for adjuvanting low pDNA vaccine doses. The highest level of protection at the lowest pDNA doses was provided by Vaxfectin p (TM)-formulated NP + M2. Vaxfectin (TM) adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin (TM)-formulated pDNA encoding NP + M2 consensus proteins.